Funding round brings in $25 million for Versartis

01/16/2013 | American City Business Journals

Versartis secured $25 million from new and existing investors in a Series C financing round. Proceeds will support clinical trials of VRS-317, an investigational once-monthly form of recombinant human growth hormone designed for children with growth hormone deficiency. "With this substantial funding, we are able to continue our comprehensive development program for VRS-317, including obtaining proof-of-concept efficacy results and preparing for the launch of a Phase III trial in 2014," Versartis CEO Jeffrey Cleland said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA